Share Name Share Symbol Market Type Share ISIN Share Description
Sensyne Health Plc LSE:SENS London Ordinary Share GB00BYV3J755 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.54% 92.50 20,485 08:22:27
Bid Price Offer Price High Price Low Price Open Price
91.00 94.00 93.00 92.50 93.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.14 -18.99 -19.00 119
Last Trade Time Trade Type Trade Size Trade Price Currency
16:42:39 O 125 92.50 GBX

Sensyne Health (SENS) Latest News

More Sensyne Health News
Sensyne Health Investors    Sensyne Health Takeover Rumours

Sensyne Health (SENS) Discussions and Chat

Sensyne Health Forums and Chat

Date Time Title Posts
20/10/202018:03Sensyne Health - Clinical AI273
27/11/201912:04Sensyne Health PLC83

Add a New Thread

Sensyne Health (SENS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sensyne Health trades in real-time

Sensyne Health (SENS) Top Chat Posts

Sensyne Health Daily Update: Sensyne Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SENS. The last closing price for Sensyne Health was 92p.
Sensyne Health Plc has a 4 week average price of 58p and a 12 week average price of 31p.
The 1 year high share price is 125p while the 1 year low share price is currently 26.50p.
There are currently 128,571,514 shares in issue and the average daily traded volume is 79,351 shares. The market capitalisation of Sensyne Health Plc is £118,928,650.45.
billy3: Another agreement today RNS Number : 8455A Sensyne Health PLC 01 October 2020 Sensyne Health and NHS Greater Glasgow and Clyde sign data access agreement Oxford, U.K. 1 October 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces it has signed a non-exclusive data sharing agreement with NHS Greater Glasgow and Clyde ("NHSGGC") giving Sensyne access to three separate anonymised patient data sets in three specific disease areas including cardiovascular disease. The anonymised patient data will be used by Sensyne to undertake medical research using Clinical AI, improve pharmaceutical development and help deliver better patient care. NHSGGC is one of 14 regional NHS Boards in Scotland. It serves a population of 1.14 million and employs around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK including 35 Hospitals of different types. The agreement falls under the Glasgow Safe Haven partnership between NHS Greater Glasgow and Clyde and the University of Glasgow, designed to provide secure access to NHS and other health datasets derived from diverse sources across the health service. The Glasgow Safe Haven is accredited by the Scottish Government as an accredited Safe Haven, and is one of four regional Safe Havens across Scotland. By enabling researchers to link data from different sources, Safe Havens encourage data-driven health research to improve health services, design better treatments, and to create innovative new health products to support better health in Scotland. Prof Julie Brittenden, Director of Research and Innovation, NHS Greater Glasgow and Clyde, said: "We are pleased to collaborate with Sensyne on data-driven approaches which aim to ultimately improve early diagnosis and treatment of various illnesses, including cardiovascular disease. The project will use anonymised patient data within the secure Glasgow Safehaven to test Sensyne's machine learning models. This is one of many of our collaborations with industry to improve research and development in order to benefit our patients in future." Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "We are delighted to be working with one of the largest NHS Boards in Scotland on data analysis to improve patient care and accelerate medical research. Adding this data sharing agreement to our Strategic Research Agreements expands our access to anonymised patient data to now cover 3.9 million patients." -ENDS-
billy3: RNS Number : 6245A Sensyne Health PLC 30 September 2020 Sensyne Health announces collaboration with the University of Oxford to provide software for remote symptom data collection and analytics for a Phase II clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19 Highlights : · Sensyne's software for remote symptom data collection and analytics will support researchers in academia and the pharmaceutical industry to undertake clinical trials during the pandemic, particularly within the community environment · Collaboration with the University of Oxford for the AVID-CC Phase II clinical trial in care homes of the anti-TNF drug adalimumab funded by the Wellcome Trust · Further agreements to use Sensyne's capabilities in other clinical trials are in advanced discussions Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces a collaboration with the University of Oxford in which Sensyne will provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19. The trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from an array of public and philanthropic donors. The purpose of the trial is to assess the effectiveness of Adalimumab in preventing progression to respiratory failure or death due to COVID-19 infection. A particular feature of this trial, supported by Sensyne's software, is the remote collection of data on symptoms, vital signs and activities of daily living from clinical trial subjects in care homes, followed by a phase of exploratory data analysis using Sensyne's machine learning algorithms. The software is based on Sensyne's CVm-Health ™ software application for tracking COVID-19 symptoms launched earlier this year. The use of CVm-Health will allow clinical trial participants in care homes to record their symptoms and vital signs and enable trial investigators to access such data remotely. The 'Good Neighbour' aspect of CVm-Health, whereby a carer, with consent, can enter data on behalf of an individual, is an important feature that facilitates clinical trials in the community care environment. Under the trial protocol, and with the consent of participants, anonymised data recorded by the application during the trial will be analysed using machine learning algorithms developed by Sensyne. Sensyne is in advanced discussions for the use of its remote symptom and vital sign data collection software and analytics expertise by other clinical researchers seeking to undertake drug trials during the COVID-19 pandemic, particularly trials within community settings such as care homes. Further announcements will be made as such discussions reach agreement. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic. We are delighted to be working with the University of Oxford on this important new trial of Adalimumab , pioneering new clinical research techniques in the community environment." Professor Duncan Richards FRCP, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU), formerly Head of Clinical Pharmacology and Experimental Medicine for GSK (until 2019), who is the Chief Investigator for the AVID-CC trial , said: " We have been impressed by Sensyne Health's digital health and clinical AI capabilities. We are excited by the opportunity that that flexible electronic diaries for remote data collection and analytics, such as CVm-Health for patients and carers to contribute to information collected in clinical trials. This pandemic has highlighted the need to re-examine the ways in which we collect data. We are delighted to be working with Sensyne and are excited by the potential for unique insights that may come from exploratory analyses of the anonymised clinical trial data using their proprietary machine learning algorithms." -ENDS-
rambutan2: At last! Oxford, U.K. 29 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, notes that on 5 June 2020, Acacia Research Corporation (Nasdaq: ACTG) announced that it had entered into an agreement with Link Fund Solutions Limited ("LFS") to purchase shares in a number of public and private life sciences companies from the LF Equity Income Fund which was previously managed by Woodford Investment Management Limited. The agreement was structured to take ownership of portfolio positions in a staged manner. Sensyne Health welcomes Acacia Research as an 11.8% shareholder and the clarity brought to the market with this announcement for the previously anticipated share transfer. Clifford Press, CEO of Acacia Research , commented: " We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth."
billy3: Full year results are tomorrow Notice of Full Year Results Oxford, UK; 23 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") , the Clinical AI company, will announce its Full Year Results for the 12 months ended 30 April 2020 on Wednesday 30th September 2020. Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 14.00 BST on the day of the results. Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact -ENDS-
rambutan2: A BIG tick: Oxford, U.K. 10 September 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020. Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems. Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister's Delivery Unit. Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne's unique business model and ethical approach to the use of clinical AI." Michael Macdonnell, said: "Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world." htTps://
parvez: SENSE partnership with Microsoft bodes well
rambutan2: Current mkt cap £40.5m, cash at start of May £31.5m. I relistened to the interims webcast: htTps:// I reread the y/e trading statement: I'm not a fan of broker's forecasts. But both Liberum and Peel Hunt have target prices, reiterated often this year, of multiples of the current price. They are expecting the apps business to be very profitable in the States. Whilst Lord Drayson hasn't covered himself in glory, he is driven, he has a very good contacts book and he has a lot of skin in the game. The team in Oxford, with its links into the university, is cutting edge. Bayer and Roche, with their huge resources and pick of the world, chose to use them. So, I think that sometime over the next 12mths SENS will emerge from what is/has been a horrible negative loop and anyone buying at the current price will do well. imho
the stigologist: Very odd comment for a Company whose share price (equity currency) and cash are both depleting Obviously they must be expecting share price to improve and understand they are in a land grab phase so it's 'eat or be eaten' ? I would point once again to ETX E-therapeutics Mkt Cap £10m PYC Physiomics Mkt Cap £2m which look crazily undervalued when Private UK Unicorns like Exscientia and BenevolentAI valued at $1000m+ (vs SENS at £60m Mkt with £40m cash) htTps:// Sensyne Health on the acquisition trail to halt decline in share ... Sensyne Health said that it was “exploring a small number of strategic [mergers and acquisitions] opportunities that have the potential to scale our businessmore quickly to achieve a leadership position in the clinical artificial intelligence market and create value for shareholders”.
mrc2u: >>gilesyDisagree that most CEOs would have been sacked because of SENS share price performance. They raised a stack of cash at IPO to pursue a plan and are getting on with it. They claim up front to have hit all the 24 month objectives from IPO early. No reason to fire a CEO for setting out a plan, getting it funded and then delivering against it. The bonus shambles is the only reason so far to fire Drayson and he has at least tried to deploy some fig leaves on thatSENS shares down from 175p to 50p giving a market cap of around GBP60m. Worth looking at private company Benevolent AI, where Woodford also had a big stake. Its value on latest raise was halved from USD2bn to USD1bn. Latest results show revenue of GBP6m and cash consumed if GBP50m. If SENS does get revenues north of GBP2m, which looks likely, and burns about 15m it ought to be worth more than one twelfth of Benevolent after a huge crash in Benevolent's valie. It would also still have 18 months to two years cash left with any additional revenues extending the runwayYes it's hard to value this. You have merely shown that it is easy to troll itMrC
Sensyne Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Sensyne He..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 18:59:47